Genmab A (GMAB) Non Operating Income (2018 - 2026)
Genmab A (GMAB) posted Non Operating Income of -$106.0 million for Q1 2026, down 174.65% on a QoQ basis from $142.0 million in Q3 2025, and down 289.29% year-over-year from $56.0 million in Q1 2025.
Genmab A (GMAB) Non Operating Income (2018 - 2026) Analysis & Trends
Genmab A's Non Operating Income history runs 6 years deep, the most recent figure standing at -$106.0 million for Q1 2026.
- Quarterly Non Operating Income fell 289.29% year-over-year to -$106.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $239.0 million (down 28.87% YoY) and the FY2025 annual result came in at $139.0 million, down 60.73% from the prior year.
- Non Operating Income was -$106.0 million for Q1 2026 at Genmab A, down from $142.0 million in the prior quarter.
- Across five years, Non Operating Income topped out at $147.0 million in Q3 2024 and bottomed at -$106.0 million in Q1 2026.
- A 3-year average of $74.4 million and a median of $133.0 million in 2024 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2025 — Non Operating Income retreated 3.4% — and 2026, when it sank 289.29%.
- Genmab A's Non Operating Income stood at $147.0 million in 2024, then retreated by 3.4% to $142.0 million in 2025, then tumbled by 174.65% to -$106.0 million in 2026.
- Business Quant data shows GMAB's Non Operating Income at -$106.0 million in Q1 2026, $142.0 million in Q3 2025, and $56.0 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Genmab A | 1.89 Bn | 366.92 Mn | 831.00 Mn | -106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -106.00 Mn |
| Sep 30, 2025 | 142.00 Mn |
| Mar 31, 2025 | 56.00 Mn |
| Sep 30, 2024 | 147.00 Mn |
| Mar 31, 2024 | 133.00 Mn |
| Sep 30, 2020 | -187.00 |
| Dec 31, 2019 | 348.00 |
| Sep 30, 2019 | 348.55 Mn |
| Dec 31, 2018 | 30.43 Mn |